Cargando…

The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges

BACKGROUND: Metreleptin, a recombinant analog of human leptin, is an approved therapy, adjunct to diet, to treat the metabolic complications of leptin deficiency in patients with lipodystrophy – a group of rare diseases characterized by a paucity of adipose tissue. MEASuRE (Metreleptin Effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Haymond, Morey W, Araújo-Vilar, David, Balser, John, Lewis, James H, Louzado, Ruth, Musso, Carla, von Schnurbein, Julia, Wabitsch, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214317/
https://www.ncbi.nlm.nih.gov/pubmed/37237416
http://dx.doi.org/10.1186/s13023-023-02714-5
_version_ 1785047814660685824
author Haymond, Morey W
Araújo-Vilar, David
Balser, John
Lewis, James H
Louzado, Ruth
Musso, Carla
von Schnurbein, Julia
Wabitsch, Martin
author_facet Haymond, Morey W
Araújo-Vilar, David
Balser, John
Lewis, James H
Louzado, Ruth
Musso, Carla
von Schnurbein, Julia
Wabitsch, Martin
author_sort Haymond, Morey W
collection PubMed
description BACKGROUND: Metreleptin, a recombinant analog of human leptin, is an approved therapy, adjunct to diet, to treat the metabolic complications of leptin deficiency in patients with lipodystrophy – a group of rare diseases characterized by a paucity of adipose tissue. MEASuRE (Metreleptin Effectiveness And Safety Registry) is a post-authorization, voluntary registry that gathers long-term safety and effectiveness data on metreleptin. Here, we present the aims and evolution of MEASuRE. METHODS: MEASuRE was established to collect data from patients receiving commercially supplied metreleptin in the United States (US) and European Union (EU). MEASuRE aims to determine the incidence and severity of safety events and describe the clinical characteristics and therapeutic outcomes in the metreleptin-treated population. A key feature of MEASuRE is that it accumulates data from different sources to meet post-authorization objectives. US data are received directly from treating physicians via a contract research organization-mediated electronic data capture system. In the EU, data are received via the European Registry of Lipodystrophies managed by the European Consortium of Lipodystrophies (ECLip), a platform established by researchers and physicians to advance the knowledge of lipodystrophy. MEASuRE complies with applicable regulatory requirements governing privacy, and the storage, management, and access of data. RESULTS: Leveraging processes, infrastructure, and data from the ECLip registry presented several challenges that were addressed during MEASuRE’s development, including the expansion of the ECLip registry to accommodate MEASuRE-specific data elements, extensive data matching processes to ensure data consistency regardless of source, and rigorous data validation following the amalgamation of global data. Through the support of ECLip, MEASuRE is now a fully operational registry with the capacity for gathering and integrating standardized US- and EU-derived data. As of 31st October 2022, 15 US and four EU sites have participated in the MEASuRE, enrolling 85 patients globally. CONCLUSIONS: Our experiences show that a post-authorization product registry can be successfully integrated into an existing patient registry. We propose that, through collaboration with existing registries and use of their established resources, patient enrolment timelines and data collection for new registries can be expedited. The learnings presented here may be applicable to other registries with similar objectives. TRIAL REGISTRATION: NCT02325674; Registered 25 December 2014 - Retrospectively registered’. https://clinicaltrials.gov/ct2/show/NCT02325674.
format Online
Article
Text
id pubmed-10214317
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102143172023-05-27 The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges Haymond, Morey W Araújo-Vilar, David Balser, John Lewis, James H Louzado, Ruth Musso, Carla von Schnurbein, Julia Wabitsch, Martin Orphanet J Rare Dis Research BACKGROUND: Metreleptin, a recombinant analog of human leptin, is an approved therapy, adjunct to diet, to treat the metabolic complications of leptin deficiency in patients with lipodystrophy – a group of rare diseases characterized by a paucity of adipose tissue. MEASuRE (Metreleptin Effectiveness And Safety Registry) is a post-authorization, voluntary registry that gathers long-term safety and effectiveness data on metreleptin. Here, we present the aims and evolution of MEASuRE. METHODS: MEASuRE was established to collect data from patients receiving commercially supplied metreleptin in the United States (US) and European Union (EU). MEASuRE aims to determine the incidence and severity of safety events and describe the clinical characteristics and therapeutic outcomes in the metreleptin-treated population. A key feature of MEASuRE is that it accumulates data from different sources to meet post-authorization objectives. US data are received directly from treating physicians via a contract research organization-mediated electronic data capture system. In the EU, data are received via the European Registry of Lipodystrophies managed by the European Consortium of Lipodystrophies (ECLip), a platform established by researchers and physicians to advance the knowledge of lipodystrophy. MEASuRE complies with applicable regulatory requirements governing privacy, and the storage, management, and access of data. RESULTS: Leveraging processes, infrastructure, and data from the ECLip registry presented several challenges that were addressed during MEASuRE’s development, including the expansion of the ECLip registry to accommodate MEASuRE-specific data elements, extensive data matching processes to ensure data consistency regardless of source, and rigorous data validation following the amalgamation of global data. Through the support of ECLip, MEASuRE is now a fully operational registry with the capacity for gathering and integrating standardized US- and EU-derived data. As of 31st October 2022, 15 US and four EU sites have participated in the MEASuRE, enrolling 85 patients globally. CONCLUSIONS: Our experiences show that a post-authorization product registry can be successfully integrated into an existing patient registry. We propose that, through collaboration with existing registries and use of their established resources, patient enrolment timelines and data collection for new registries can be expedited. The learnings presented here may be applicable to other registries with similar objectives. TRIAL REGISTRATION: NCT02325674; Registered 25 December 2014 - Retrospectively registered’. https://clinicaltrials.gov/ct2/show/NCT02325674. BioMed Central 2023-05-26 /pmc/articles/PMC10214317/ /pubmed/37237416 http://dx.doi.org/10.1186/s13023-023-02714-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Haymond, Morey W
Araújo-Vilar, David
Balser, John
Lewis, James H
Louzado, Ruth
Musso, Carla
von Schnurbein, Julia
Wabitsch, Martin
The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges
title The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges
title_full The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges
title_fullStr The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges
title_full_unstemmed The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges
title_short The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges
title_sort metreleptin effectiveness and safety registry (measure): concept, design and challenges
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214317/
https://www.ncbi.nlm.nih.gov/pubmed/37237416
http://dx.doi.org/10.1186/s13023-023-02714-5
work_keys_str_mv AT haymondmoreyw themetreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT araujovilardavid themetreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT balserjohn themetreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT lewisjamesh themetreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT louzadoruth themetreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT mussocarla themetreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT vonschnurbeinjulia themetreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT wabitschmartin themetreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT themetreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT haymondmoreyw metreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT araujovilardavid metreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT balserjohn metreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT lewisjamesh metreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT louzadoruth metreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT mussocarla metreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT vonschnurbeinjulia metreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT wabitschmartin metreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges
AT metreleptineffectivenessandsafetyregistrymeasureconceptdesignandchallenges